Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer